BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F]fluoro-2-deoxy-d-glucose uptake ability

Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1

(2009) J. C. Ricarte-Filho et al.   CANCER RESEARCH

High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma

(2009) Y. C. Henderson et al.   CLINICAL CANCER RESEARCH

Prognostic utility of BRAF mutation in papillary thyroid cancer

(2009) Mingzhao Xing   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation

(2009) Linwah Yip et al.   SURGERY

Advances in Male Contraception

(2008) Stephanie T. Page et al.   ENDOCRINE REVIEWS

BRAFV600EMutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

(2008) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Thyroid carcinoma: molecular pathways and therapeutic targets

(2008) Yuri E Nikiforov   MODERN PATHOLOGY

Molecular characteristics in papillary thyroid cancers (PTCs) with no131I uptake

(2007) Caterina Mian et al.   CLINICAL ENDOCRINOLOGY

Clinicopathological Analysis of Papillary Thyroid Cancer withPIK3CAAlterations in a Middle Eastern Population

(2007) Jehad Abubaker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM